#United States #Private Placement #Jersey City, N.J. #WallachBeth Capital #bioAffinity Technologies

WallachBeth Capital Announces Private Placement

On August 13, 2026, WallachBeth Capital, a prominent firm in capital markets and institutional execution, revealed its latest initiative to support bioAffinity Technologies, Inc. This biotechnology company specializes in noninvasive diagnostics, particularly focusing on the early detection of cancer. The new securities purchase agreement with an institutional investor entails the sale of 8,462,027 shares of common stock, along with pre-funded warrants and associated purchase options, in a private placement offering priced per current Nasdaq regulations.

Details of the Offering

The private placement has been priced at an effective offering price of $0.4727 for each share of common stock, including two warrants that allow investors to purchase up to a combined total of 16,924,054 shares. Alternatively, the pre-funded warrants are priced at $0.4657 each, allowing further flexibility for investors looking to partake in this growth opportunity within the biotech sector. The warrants are designed to empower shareholders with options; they carry an exercise price of $0.4727 per share and an expiration term of five years from the issue date, contingent upon shareholder approval.

The anticipated gross proceeds from this strategic offering are around $4 million, although precise figures will be finalized after accounting for placement agent fees and other pertinent costs associated with the offering process. The transaction is projected to close around August 14, 2026, contingent upon meeting standard closing conditions.

The Role of WallachBeth Capital

As the sole placement agent in this initiative, WallachBeth Capital plays a pivotal role in navigating the complexities of capital markets to ensure that bioAffinity Technologies can effectively pursue its objectives. Their reputation for connecting corporate clients with leading institutions enhances the procedure, facilitating the journey from concept to reality in funding. WallachBeth specializes in various investment services, including initial public offerings and private transactions, making them a key partner for bioAffinity Technologies at this crucial growth stage.

Significance of This Private Placement

The relevance of this offering extends beyond mere financing; it signifies a robust commitment to advancing diagnostic capabilities within the healthcare sector. bioAffinity Technologies is at the forefront of innovation, developing technologies that promise noninvasive methods for cancer screening—an essential component in improving patient outcomes and potentially saving lives.

Legal Considerations

It is essential to note that the securities sold through this private placement will not be registered under the Securities Act of 1933. Thus, these securities cannot be reoffered or resold in the United States unless they comply with an effective registration statement or meet an appropriate exemption. Customary registration rights will be provided for shares linked to the warrants, ensuring appropriate legal frameworks are adhered to.

Looking Ahead

This strategic movement reflects not only the health of bioAffinity Technologies but also larger market trends that favor innovative healthcare solutions. With WallachBeth Capital at the helm, it lends credence to the belief that future healthcare advancements must prioritize early detection and noninvasive methods. As the industry adapts and evolves, this partnership marks a significant milestone in the support of biotech companies that are addressing critical healthcare challenges.

In conclusion, this private placement not only embodies a financial transaction but also serves as a beacon for future innovation in noninvasive cancer diagnostics, highlighting the promise and necessity of continued investment in healthcare technologies.